Introduction: We evaluated the efficacy and safety of the recommended scheme by international guideline in 2012 (2012’s scheme) in comparison with a less aggressive scheme (2019’s scheme) proposed by Umpierrez et al.

Methods: A non-blinded randomized clinical study was conducted in which two short-time insulin schemes for hyperglycemic control (2012’s vs. 2019’s) were compared in hospitalized patients of Hospital Universitario Clínica San Rafael (HUCSR) in Bogotá Colombia in a period between october 2019 and february 2022.

Results: Totally, 91 patients joined the trial. There were no statically significant difference between the demographic characteristics and outcomes.

Conclusions: The two schemes are equally safe and efficient in our population and can be used interchangeably.


C. A. Yepes: Speaker’s Bureau; Medtronic, Novo Nordisk, Sanofi. J. M. Mora: None. E. Moscoso: None. J. R. Rodríguez: None. L. A. León: None. J. Gomez: None. N. Buriticá: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at